Eyenovia, Inc. announced on January 6, 2025, that it has engaged Chardan as its financial advisor to assist in the evaluation of strategic alternatives. This review encompasses a full range of options, including a business combination, sale of the company, reverse merger, asset sale, or a combination of these alternatives.
The company will continue to carefully manage its expenses during this process. Alongside the strategic review, Eyenovia is progressing with the development of its advanced Optejet device, exploring options for its use as a consumer 'user-filled' product.
The user-filled product is expected to advance through a device regulatory pathway without the need for clinical trials and could potentially be commercially available by the end of 2025. Eyenovia has not set a timetable for the conclusion of its strategic review.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.